Dignitana, Inc. Appoints Three Board Members in U.S. And Names James McKinney President and Chief Operating Officer

Lund, Sweden - 9 March 2018 - Dignitana AB, world leader in medical scalp cooling technology, today announced the appointment of Anette Cronström, Thomas Joyce and Thomas Kelly to the Board of Directors for Dignitana, Inc., which governs operations in the U.S. and met this week in Dallas, Texas

Also announced is the promotion of James McKinney who will now serve as President and Chief Operating Officer of Dignitana, Inc.. McKinney has been the company's Chief Operating Officer since November 2016.

"We are honored to bring these experienced leaders onto the Dignitana, Inc. Board here in the U.S.," said William Cronin, CEO of Dignitana AB. "Their proven strengths and long-standing expertise, especially in the finance of both domestic and international business, will be a tremendous asset to our continued growth and development. The addition of these accomplished professionals with the newly announced changes to the AB Board bring to Dignitana a global governance structure cthat will help this company move into its next and most important phase of growth"

"Jim McKinney's leadership and healthcare experience have brought enormous value to Dignitana since he joined us in 2016," Cronin adds. "As we continue to expand and introduce new innovations to the market we are enormously fortunate to have his operational insights and wisdom guiding our team."

"Dignitana, Inc. has seen exponential growth in the last two years," said James McKinney, President and COO of Dignitana, Inc. "The size and strength of our U.S. team continues to increase as we respond to the needs of our clinical partners, and we are excited to be moving forward with the addition of these accomplished business leaders to our Board."

Anette Cronström, Board Member

Born 1966

Since 2016 Anette Cronström has served as the Director of International Accounting for GameStop Inc., a Fortune 500 company containing specialty retail brands that make the most popular technologies affordable and simple. Previous positions held at GameStop Inc. include Director of Global Internal Audit and Compliance and Director of International Audit and Compliance. Prior to joining GameStop Inc., Ms. Cronström served as the Finance Director of GameStop Nordic and as the CFO of ProstaLund Operations AB. She is a graduate of the University of Lund's Business School, where studied Business Administration and Economics.

Thomas Joyce, Board Member

Born 1955

Thomas Joyce is a recognized leader in the financial services industry with experience in domestic and international markets, regulatory reform, trading, technology, and client service. Most recently, Mr. Joyce served as the Executive Chairman of Arxis Capital, a spinout of Bank of America. Prior to Arxis he was Chairman and Chief Executive Officer of Knight Capital Group, from which he retired in July of 2013, and was Head of Global Trading at Sanford C. Bernstein & Co. Mr. Joyce is widely credited for rebuilding Knight into an industry leader, taking the company from less than $500 million in annual revenues and losing money, to approximately $1.2 billion in revenues with $250 million in pre-tax earnings a decade later. Earlier in his career, he spent close to fifteen years at Merrill Lynch where he managed several major equity businesses. Mr. Joyce is most recently a former member of the Securities Industry and Financial Markets Association (SIFMA) Board of Directors as well as a former member of the NASDAQ Board of Directors. He attended Harvard University where he obtained a degree in economics and where he is also a member of the Harvard Varsity Club's Athletics Hall of Fame.

Currently he is on the Board of Directors of Sandboxx, LLC, and Clearpool, Inc. He is also a member of SAG-

AFTRA.

Thomas N. Kelly, Board Member

Born 1963

Thomas Kelly serves as Managing Director of KMK & Associates LLC, a private equity firm with a wide range of interests from agriculture to manufacturing. He is also a Director of The Leaders Bank, headquartered in Oak Brook, Illinois. With diverse leadership roles in numerous companies and civic organizations, Mr. Kelly is a trusted and experienced leader known for his ability to anticipate and navigate business challenges with accountability and transparency. He serves on the Boards of the Donald P. and Byrd M. Kelly Foundation, which primarily supports Catholic education in the Chicago area. He attended the University of Kansas in Lawrence, and is an active alumnus serving as member of the KUAA President's Advisory Council.

Current Board Positions include the pending shareholder approval as Chair of Dignitana AB Board of Directors, Managing Member of KMK & Associates LLC, Director of Leaders Bank, Director of Grandstand Sportswear and Glassware, Managing Member of 3840 Greenway Circle LLC, Managing Member of Harger Woods Corporate Center LLC, Managing Member of D.P. Kelly & Associates, Director of Elarasys Worldwide LLC, Vice President of Emerald Air Co., Director of Entrust Services, and former Director of Whitnell & Co., Director of Continental Community Holdings, Director and Secretary of Donald P. and Byrd M. Kelly Foundation.

James O. McKinney, Board Member, President and COO, Dignitana, Inc.

Born 1953

Jim McKinney currently serves as a Healthcare Consultant to Catholic Relief Services and is a Real Estate Investor at McKinney & Hess Properties. Previously he has served as Division CEO of Anesthesia Group, Division President of Iasis Healthcare, President and COO of Leland Medical, Inc., and President and CEO of Brim Healthcare, Inc. A seasoned healthcare executive, he has extensive experience and a proven track record in leadership and operations, including acquisitions, physician relations and partnerships, program design and implementation, financial performance, and system integration.

Investor Relations                                                       

Melissa Bourestom                                       
Dignitana                                                       
00 1 773 387 8504                                         
investorrelations@dignitana.com                 

Media Contact   

Caren Browning 
King + Company
00 1 212 561 7464
caren.browning@kingcompr.com

About Dignitana AB (publ)

Dignitana is a Swedish public company based in Lund and manufacturer of the medical cooling device DigniCap®. Dignitana AB is listed on Nasdaq First North Stockholm and has appointed Erik Penser Bank as Certified Adviser. Headquartered in Dallas Texas, Dignitana, Inc. is the U.S. subsidiary of Dignitana AB. For more information visit www.dignitana.se and www.dignicap.com

This information is information that Dignitana AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, by the above contact, for publication at 17:30 (CET), 9 March 2018.

Dignitana CEO William Cronin to Speak at Aktiedagen Stockholm

Dignitana AB announces that Chief Executive Officer William Cronin will speak at Aktiedagen Stockholm on 19 March 2019 at 15:00 CET.



Dignitana AB Taps oneservice as Service Provider in Europe

Dignitana AB, manufacturer of The DigniCap® Scalp Cooling System, announces today that it has partnered with oneservice, a global provider of specialty technical services, to provide service and maintenance to facilities offering DigniCap in Europe.


Dignitana AB Publishes Year End Report for 2018

Results and financial position

Significant events during the period

  • Sales for the period amounted to 8,772 TSEK, $971 KUSD, an increase of 34 percent compared to the same period in 2017.
  • EBITDA amounted to (2,996) TSEK, ($335) KUSD, a 72 percent improvement compared to the same period in 2017.
  • U.S. annual revenue increased 52 percent over 2017.
  • Contracts for 8 units were placed globally.
  • Contracts were signed for 13 U.S. locations.
  • U.S. fourth quarter revenue increased 18 percent over fourth quarter 2017.
  • On 8 October Dignitana announced that Mr. Greg Dingizian, via his Adma Förvaltnings AB investment vehicle, had accumulated 10.4 percent of the outstanding common shares of the company.
  • On 14 November Dignitana announced the establishment of a clinical trial at Beijing University Cancer Hospital in conjunction with Konica Minolta.
  • In December the company completed rights and directed equity issues providing the Company with approximately SEK 33.8M before issue costs.

Rättelse - sista dag för handel med BTA i Dignitana AB (publ) är idag den 29 januari 2019

Sista dag för handel i Dignitanas betalda tecknade aktier, DIGN BTA, är tisdagen den 29 januari 2019. De nya aktierna beräknas att synas på VP-konton och depåer måndagen den 4 februari 2019.


Amendment - Last day of trading of paid-up shares in Dignitana AB (publ) is today, the 29 of January 2019

The last day of trading in Dignitana's paid-up shares, DIGN BTA, is Tuesday 29 January 2019. The new shares are estimated to be available in VP-accounts and depots Monday 4 February 2019.


Sista dag för handel med BTA i Dignitana AB (publ)

Sista dag för handel i Dignitanas betalda tecknade aktier, DIGN BTA, är onsdagen den 30 januari 2019. De nya aktierna beräknas att synas på VP-konton och depåer måndagen den 4 februari 2019.


Last day of trading of paid-up shares in Dignitana AB (publ)

The last day of trading in Dignitana's paid-up shares, DIGN BTA, is Wednesday 30 January 2019. The new shares are estimated to be available in VP-accounts and depots Monday 4 February 2019.


Dignitana offentliggör utfallet för företrädesemissionen och de riktade emissionerna

Teckningsperioden för Dignitana ABs ("Dignitana" eller "Bolaget") nyemission med företrädesrätt för Bolagets aktieägare löpte ut den 18 december 2018. Företrädesemissionen omfattades av teckningsförbindelser och garantiåtaganden upp till 100 procent av det totala emissionsbeloppet, som högst kunde uppgå till ca 24,3 MSEK. Utfallet visar att 5 383 686 aktier, motsvarande cirka 93 procent av Företrädesemissionen, tecknades med stöd av teckningsrätter och att 408 917 aktier, motsvarande cirka 7 procent av Företrädesemissionen, tecknades utan stöd av teckningsrätter. Totalt tecknades 1 517 201 aktier utan företrädesrätt innebärande att företrädesemissionen tecknades till ca 119 procent.   Genom företrädesemissionen tillförs Bolaget ca 24,3 MSEK före emissionskostnader. Emissionsgarantin har inte tagits i anspråk.


Dignitana Announces the Outcome of the Rights Issue and the Directed Issues

The subscription period for Dignitana AB's ("Dignitana" or "the Company") rights issue with preferential right for the Company's shareholders ended on 18 December 2018. The rights issue was covered by subscription commitments and guarantees up to 100 percent of the total amount in the Issue, corresponding to approximately SEK 24.3M. 5,383,686 shares, corresponding to 93 percent of the rights issue, was subscribed for with subscription rights and 408,917 shares, corresponding to approximately 7 percent of the rights issue, was subscribed for without subscription rights. In total, 1,517,201 shares were subscribed for without subscription right, implying that the rights issue was subscribed for to approximately 119 percent and the Company will receive approximately SEK 24.3M before issue costs. There will be no need to utilize the guarantee obligations that have been provided. 


Dignitana och ThermoTek har slutit avtal om kontraktsutveckling och produktion av nästa generations skalpkylningssystem

DigniCap Delta bygger på en avancerad kylteknik som minimerar håravfall vid kemoterapi

Dignitana AB, som tillverkar DigniCap® skalpkylningssystem, inleder ett samarbete med ThermoTek, Inc. för att utveckla DigniCap Delta, en avancerad modell av det FDA-godkända skalpkylningssystemet DigniCap från 2015. Den nya versionen är en mindre och smidigare enhet för behandling av en patient åt gången med en nydesignad, engångskylmössa.
FDA-godkännande för den nya enheten väntas komma under våren 2019.


Dignitana Partners with ThermoTek to Develop Next Generation in Scalp Cooling

DigniCap Delta brings advanced cooling technology to minimize hair loss from chemotherapy 

Dignitana AB, manufacturer of The DigniCap® Scalp Cooling System, has partnered with ThermoTek, Inc. to develop the DigniCap Delta, an advanced model of the 2015 FDA-cleared DigniCap Scalp Cooling System, featuring a new single-patient use cap design and a smaller, more streamlined single-patient machine. U.S. Food and Drug Adminstration clearance for the new device is anticipated in spring 2019.


Dignitana kompletterar den tidigare aviserade riktade emissionen med ytterligare en riktad emission

Styrelsen i Dignitana AB (publ) har idag beslutat, pga stort intresse, komplettera den tidigare aviserade riktade emissionen, genom att emittera ytterligare 540 000 aktier till ett belopp om 2,3 MSEK. Sammantaget innebär detta att de riktade emissionerna omfattar totalt 9,5 MSEK.


Dignitana complements the previously announced directed rights issue - decides on an additional directed rights issue

The Board of Directors of Dignitana AB (publ) has decided today, as a result of a large investor interest, to complement the previously announced directed rights issue by emitting 540,000 additional shares to an amount of approximately SEK 2.3M. In total this implies that the directed rights issues comprise a total of SEK 9.5M.


Dignitana offentliggör Informations-Memorandum

Styrelsen i Dignitana AB (publ) offentliggör härmed ett Informations-Memorandum med anledning av förestående företrädesemission. Memorandumet finns nu tillgängligt på bolagets hemsida, www.dignitana.se.


Dignitana AB Publishes Information Memorandum

The Board of Directors of Dignitana AB (publ) hereby publishes an Information Memorandum on the announced rights issue. The Information Memorandum is attached here and is published today on the Company's webpage,www.dignitana.com.


Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Sturegatan 32
114 36 Stockholm

08-692 21 90
Kontaktformulär

Kontakta oss

Vill du veta mer om beQuoted och våra tjänster så fyll i nedanstånde uppgifter och tryck skicka.

En av våra rådgivare kontaktar dig inom kort.

Namn: Telefon: E-postadress: Meddelande: